Biologyarticle2026-10-07

Sodium butyrate-mediated HDAC inhibition under hypoxic conditions modulates redox balance and tumor cell behavior in MCF-7 human breast cancer cells

Open access0 citations

Abstract

Abstract Hypoxia and epigenetic dysregulation are key contributors to breast cancer progression and therapeutic resistance. However, the interaction between histone deacetylase (HDAC) inhibition and hypoxia-associated signaling remains incompletely understood. This study therefore aimed to evaluate the combined effects of sodium butyrate (NaBu), an HDAC inhibitor, and cobalt chloride (CoCl 2 ), a chemical hypoxia-mimetic agent, on the biological behavior of MCF-7 breast cancer cells. To do this, cells were treated with NaBu, CoCl 2 , or their combination. Cell viability, proliferation, intracellular reactive oxygen species (ROS) generation, and cell-cycle distribution were assessed using MTT, cell counting, NBT, and flow cytometry, respectively. Quantitative real-time PCR was also performed to evaluate the expression of HDAC1 , HIF-1α , c-MET , and lncRNA-H19 . NaBu reduced cell viability and proliferation in a dose- and time-dependent manner, accompanied by increased ROS generation and HDAC1 downregulation. CoCl 2 induced a hypoxia-mimetic response characterized by HIF-1α and lncRNA-H19 upregulation and G2/Marrest, whereas prolonged or higher-dose exposure promoted ROS accumulation and growth inhibition. Combined treatment further reduced cell viability and proliferation, enhanced ROS accumulation, and modulated hypoxia-related gene expression compared with either treatment alone. Although G2/M arrest was also observed following combined treatment, the cell-cycle profile largely resembled that induced by CoCl 2 alone, suggesting that hypoxia-mimetic signaling predominantly drove this response. Overall, HDAC inhibition enhanced the cellular response to hypoxia-mimetic stress, highlighting the therapeutic potential of integrating epigenetic modulation with hypoxia-targeting strategies. Nevertheless, further mechanistic, drug-interaction, and in vivo studies are required to validate these findings.

// Source

View paper (DOI)Open access versionOpenAlexScientific ReportsPublished 2026-10-07

Authors: Hadis Yari, Sajjad Sisakhtnezhad, Ali Bidmeshkipour

Institutions: Razi University